Today: 8 June 2026
Browse Category

NASDAQ:HRMY 13 January 2026

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences shares fell 6.4% to $35.82 Tuesday after the company cut its Fragile X program and issued 2026 sales guidance. Harmony forecast Wakix net revenue of $1.0–$1.04 billion for 2026 and confirmed it will phase out ZYN002. Preliminary Wakix revenue for 2025 was about $868 million. CEO Jeffrey Dayno is set to present at the J.P. Morgan Healthcare Conference later Tuesday.
13 January 2026
·

Stock Market Today

  • U.S. Stock Market Eyes Potential Fourth Consecutive Year of Double-Digit Gains in 2026
    June 8, 2026, 1:36 PM EDT. The U.S. stock market is on track for a potential fourth consecutive year of double-digit returns in 2026, contingent on price-to-earnings ratios (P/Es) staying elevated. Historically, high P/Es-valuations that compare stock prices to earnings-have triggered investor fear, leading to declines and losses. Market watchers caution that sustaining optimism is key, but also advise diversification as a prudent approach regardless of market direction.

Latest articles

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

8 June 2026
ASML’s market value soared to a European record of $691.8 billion as analysts raised estimates for its EUV machine output, driving U.S. shares up 7.1% after JPMorgan and Morgan Stanley hiked price targets, with investors betting on ASML’s control of critical chipmaking tools amid surging AI demand and factory expansions planned for 2026.
Meta $145 Billion AI Push Faces Snag With Wall Street

Meta $145 Billion AI Push Faces Snag With Wall Street

8 June 2026
Meta shares fell 0.8% to $587.97 Monday after reports the company may sell tens of billions in new stock to fund AI infrastructure, raising investor concerns about dilution as capital spending soars and AI financing shifts from earnings to equity markets; Meta has not hired banks and may still consider other financing options.
Palantir’s $200 Target Meets Doubts on AI Growth

Palantir’s $200 Target Meets Doubts on AI Growth

8 June 2026
Palantir shares steadied at $135.73 after a volatile week, as investors weighed 85% Q1 revenue growth and a raised 2026 forecast against a steep 96x forward earnings valuation, with analysts warning that any slowdown in U.S. commercial or government revenue, or a shift in AI sentiment, could sharply impact the stock’s high multiple.
Go toTop